Mikrogen Diagnostics acquires Lophius Biosciences
Lophius Biosciences GmbH founded from the University of Regensburg in 2002 has been acquired by Mikrogen Diagnostics. Since 1989 Mikrogen GmbH in Upper Bavarian Neuried has been producing antigens for clinical diagnostics. The global supplier of system solutions for medical laboratory diagnostics offers a multitude of serological and molecular diagnostic systems. The specialty lies in the direct (PCR) and indirect detection of bacterial, viral and parasitic infections as well as of autoimmune disease and cancer. The combination of know-how in diagnostics and automation by Mikrogen with the technology from Lophius for pathogen-specific immunostimulation will facilitate novel diagnostic solutions for infectious diseases and complete the Mikrogen portfolio. Mikrogen will expand operations by taking over the entire Lophius team and the Lophius laboratories at BioPark Regensburg. In the future in-vitro diagnosis kits developed by Lophius will be marketed by Mikrogen. “We are looking forward to be able to welcome our new colleagues from Lophius on board. We believe that leading both teams together and their complementary specialist knowledge will expedite the strength of our innovation in the development of new diagnostic solutions”, said Dr. Erwin Soutschek, CEO & Managing Director of Mikrogen GmbH.